Nabumetone induces less gastrointestinal mucosal changes than diclofenac retard

被引:2
作者
Becvár, R [1 ]
Urbanová, Z [1 ]
Vlasáková, V [1 ]
Vítová, J [1 ]
Rybár, I [1 ]
Maldyk, H [1 ]
Filipowicz-Sosnowska, A [1 ]
Bernacka, K [1 ]
Mackiewicz, S [1 ]
Gömör, B [1 ]
Rojkovich, B [1 ]
Siro, B [1 ]
Bereczki, J [1 ]
Toth, K [1 ]
Sukenik, S [1 ]
Green, L [1 ]
Ehrenfeld, M [1 ]
Pavelka, K [1 ]
机构
[1] Inst Rheumatol, CZ-12850 Prague 2, Czech Republic
关键词
diclofenac; efficacy; endoscopy; nabumetone; osteoarthritis; safety;
D O I
10.1007/s100670050101
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of the study was to compare the efficacy and the effects on the mucosa of the gastrointestinal tract (CIT) of nabumetone and diclofenac retard in patients with osteoarthritis (OA), An open, multicentre, randomised, comparative, endoscopy-blind parallel group study included 201 patients with nabumetone and 193 patients with diclofenac retard suffering from moderate to severe OA of the knee or hip joint. Twelve clinical efficacy variables were assessed and a portion of the population underwent gastroduodenoscopy. All patients exhibited significant improvement in pain severity and pain relief (p<0.001 and p<0.0001, respectively) but there were no differences between the groups for all the efficacy variables. Eleven per cent of patients on nabumetone and 19% on diclofenac experienced GIT side-effects. Sixty-nine patients with nabumetone and 61 with diclofenac underwent gastroduodenoscopy. The differences in the mucosal grade for the oesophagus, stomach and duodenum at baseline were not significant. In the oesophagus there were significantly less changes after treatment with nabumetone (p = 0.007) than with diclofenac; there were similar findings in the stomach (p<0.001) but the difference in the duodenum was not significant. This study indicates that nabumetone and diclofenac retard have similar efficacy in the treatment of OA, but nabumetone has significantly fewer GIT side-effects.
引用
收藏
页码:273 / 278
页数:6
相关论文
共 13 条
[1]   COMPARISON OF THE SAFETY AND EFFICACY OF NABUMETONE AND ASPIRIN IN THE TREATMENT OF OSTEOARTHRITIS IN ADULTS [J].
APPELROUTH, DJ ;
BAIM, S ;
CHANG, RW ;
COHEN, MH ;
ENGLUND, DW ;
GERMAIN, BF ;
HARTMAN, SS ;
JAFFER, A ;
MULLEN, BJ ;
SMITH, FE .
AMERICAN JOURNAL OF MEDICINE, 1987, 83 (4B) :78-81
[2]  
BERNHARD GC, 1992, BR J REUMATOL S2, V31, P64
[3]   NABUMETONE (BRL14777,4-[6-METHOXY-2-NAPHTHYL]-BUTAN-2-ONE) - A NEW ANTI-INFLAMMATORY AGENT [J].
BOYLE, EA ;
FREEMAN, PC ;
MANGAN, FR ;
THOMSON, MJ .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1982, 34 (09) :562-569
[4]  
EVERSMEYER W, 1993, AM J MED S2A, V95, P10
[5]  
FELSON DT, 1990, RHEUM DIS CLIN N AM, V16, P499
[6]  
GABRIEL SE, 1990, J RHEUMATOL, V17, P1
[7]   ENDOSCOPIC STUDIES OF NABUMETONE IN PATIENTS WITH RHEUMATOID-ARTHRITIS - A COMPARATIVE ENDOSCOPIC AND HISTOLOGIC EVALUATION [J].
GREB, WH ;
VONSCHRADER, HW ;
CERLEK, S ;
DOMINIS, M ;
HAUPTMANN, E ;
ZENIC, N .
AMERICAN JOURNAL OF MEDICINE, 1987, 83 (4B) :19-24
[8]   COMPARATIVE GASTROINTESTINAL BLOOD-LOSS ASSOCIATED WITH PLACEBO, ASPIRIN, AND NABUMETONE AS ASSESSED BY RADIOCHROMIUM (CR-51) [J].
LUSSIER, A ;
DAVIS, A ;
LUSSIER, Y ;
ENG, P ;
LEBEL, E .
JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 29 (03) :225-229
[9]   PRECLINICAL OVERVIEW OF NABUMETONE - PHARMACOLOGY, BIOAVAILABILITY, METABOLISM, AND TOXICOLOGY [J].
MANGAN, FR ;
FLACK, JD ;
JACKSON, D .
AMERICAN JOURNAL OF MEDICINE, 1987, 83 (4B) :6-10
[10]   6-MONTH MULTICENTER STUDY COMPARING NABUMETONE WITH NAPROXEN IN THE TREATMENT OF OSTEOARTHRITIS [J].
PISKO, EJ ;
BOCKOW, BI ;
BOX, P ;
BRODSKY, AL ;
BURCH, FX ;
COLLINS, RL ;
FLEISCHMANN, RM ;
KELLER, MI ;
LIPANI, JA ;
POILEY, JE ;
ROTH, SH ;
SEARLES, RP ;
SENTER, RG .
AMERICAN JOURNAL OF MEDICINE, 1987, 83 (4B) :86-91